Neurology. 2003 Nov 25;61(10):1444-6
Department of Neurology and Neurosciences, UMDNJ-New Jersey Medical School, Newark.
A reliable screening assay for anti-interferon beta (IFNbeta) antibodies is needed for patients with multiple sclerosis (MS) receiving IFNbeta therapy.
The performance of a new ELISA method, the capture ELISA (cELISA), was assessed by comparing it to a standard IFNbeta ELISA in correlating with neutralizing antibodies measurement in 453 sera from patients with MS.
The cELISA outperformed the standard ELISA, and may be a suitable screening assay for anti-IFNbeta antibodies in IFNbeta-treated patients with MS.